Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt

被引:29
|
作者
Greenwood, Brian [1 ]
机构
[1] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England
基金
比尔及梅琳达.盖茨基金会;
关键词
Meningococcal meningitis; Africa; Vaccination; Surveillance; CONJUGATE VACCINE; BURKINA-FASO; EPIDEMIC MENINGITIS;
D O I
10.1016/j.vaccine.2012.12.035
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
For over 100 years, large epidemics of meningococcal meningitis have occurred every few years in areas of the African Sahel and sub-Sahel known as the African meningitis belt. Until recently, the main approach to the control of these epidemics has been reactive vaccination with a polysaccharide vaccine after an outbreak has reached a defined threshold and provision of easy access to effective treatment but this approach has not prevented the occurrence of new epidemics. Meningococcal conjugate vaccines, which can prevent meningococcal carriage and thus interrupt transmission, may be more effective than polysaccharide vaccines at preventing epidemics. Because the majority of African epidemics have been caused by serogroup A meningococci, a serogroup A polysaccharide/tetanus toxoid protein conjugate vaccine (PsA-TT) has recently been developed. Results from an initial evaluation of the impact of this vaccine on meningococcal disease and meningococcal carriage in Burkina Faso have been encouraging. To review how the research agenda for meningococcal disease in Africa has been changed by the advent of PsA-TT and to define a new set of research priorities for study of meningococcal infection in Africa, a meeting of 41 scientists was held in Dakar, Senegal on April 24th and 25th 2012. The research recommendations developed during the course of this meeting are presented in this paper. The need for enhanced surveillance for meningitis in defined populations with good diagnostic facilities in African countries at risk of epidemics was identified as the highest priority. This is needed to determine the duration of protection against serogroup A meningococcal disease provided by PsA-TT and to determine the risk of disease and carriage caused by meningococci of other serogroups. Other research areas given high priority included identification and validation of serological correlates of protection against meningococcal disease and carriage, development of improved methods for detecting carriage and epidemiological studies aimed at determining the reasons underlying the peculiar epidemiology of meningococcal disease in the African meningitis belt. Minutes and working papers from the meeting are provided in supplementary tables and some of the presentations made at the meeting are available on the MenAfriCar consortium website (www.menafricar.org) and on the web site of the Centers for Disease Control (www.cdc.gov).
引用
收藏
页码:1453 / 1457
页数:5
相关论文
共 50 条
  • [21] Impact of vaccination during an epidemic of serogroup C meningococcal disease in Salvador, Brazil
    Cardoso, Cristiane W.
    Silva Pinto, Lorene Louise
    Reis, Mitermayer G.
    Flannery, Brendan
    Reis, Joice N.
    [J]. VACCINE, 2012, 30 (37) : 5541 - 5546
  • [22] Molecular Characterization of Invasive Meningococcal Isolates from Countries in the African Meningitis Belt before Introduction of a Serogroup A Conjugate Vaccine
    Caugant, Dominique A.
    Kristiansen, Paul A.
    Wang, Xin
    Mayer, Leonard W.
    Taha, Muhamed-Kheir
    Ouedraogo, Rasmata
    Kandolo, Denis
    Bougoudogo, Flabou
    Sow, Samba
    Bonte, Laurence
    [J]. PLOS ONE, 2012, 7 (09):
  • [23] Risk factors for acquisition of meningococcal carriage in the African meningitis belt
    Cooper, Laura V.
    Robson, Anna
    Trotter, Caroline L.
    Aseffa, Abraham
    Collard, Jean-Marc
    Daugla, Doumagoum Moto
    Diallo, Aldiouma
    Hodgson, Abraham
    Jusot, Jean-Francois
    Omotara, Babatunji
    Sow, Samba
    Hassan-King, Musa
    Manigart, Olivier
    Nascimento, Maria
    Woukeu, Arouna
    Chandramohan, Daniel
    Borrow, Ray
    Maiden, Martin C. J.
    Greenwood, Brian
    Stuart, James M.
    Ali, Oumer
    Bedru, Ahmed
    Lema, Tsehaynesh
    Moti, Tesfaye
    Tekletsion, Yenenesh
    Worku, Alemayehu
    Xabher, Haimanot Guebre
    Yamuah, Lawrence
    [J]. TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2019, 24 (04) : 392 - 400
  • [24] Pros and cons of vaccination against serogroup B meningococcal disease
    Delgado Rodriguez, Miguel
    Dominguez Garcia, Angela
    [J]. MEDICINA CLINICA, 2018, 150 (03): : 109 - 113
  • [25] The burden of meningococcal meningitis in the African Meningitis Belt, from 2009 to 2014: a trend analysis
    Jaca, Anelisa
    Wiyeh, Alison Beriliy
    Sambala, Evanson Zondani
    Wiysonge, Charles Shey
    [J]. PAN AFRICAN MEDICAL JOURNAL, 2021, 39
  • [26] Impact of mass vaccination with polysaccharide conjugate vaccine against serogroup C meningococcal disease in Spain
    Salleras, L
    Domínguez, A
    Cardeñosa, N
    [J]. VACCINE, 2003, 21 (7-8) : 725 - 728
  • [27] Invasive meningococcal disease burden and prophylaxis: update on serogroup B vaccination
    Caceres, Rosario
    Guillen, Jaume
    Gonzalez-Inchausti, Carmen
    Gomez Sobrino, Mamen
    [J]. FARMACEUTICOS COMUNITARIOS, 2021, 13 (04): : 28 - 42
  • [28] A comparison of national vaccination policies to prevent serogroup B meningococcal disease
    Sulis, Giorgia
    Horn, Miranda
    Borrow, Ray
    Basta, Nicole E.
    [J]. VACCINE, 2022, 40 (26) : 3647 - 3654
  • [29] Control of serogroup C meningococcal disease by mass vaccination in Catalonia (Spain)
    Salleras, L
    Domínguez, A
    Prats, G
    [J]. VACCINE, 1999, 17 : S56 - S60
  • [30] Control of serogroup W meningococcal disease outbreaks: the promise of adolescent vaccination
    Mbaeyi, Sarah
    McNamara, Lucy A.
    [J]. LANCET CHILD & ADOLESCENT HEALTH, 2022, 6 (02): : 73 - 75